Clinical Trials - April 28, 2015
Trial Starts for PPMS Drug
Teva Pharmaceutical Industries Ltd. and Active Biotech enrolled the first patient in their study A RandomizedPlacebo-controlled Trial Evaluating Laquinimod in primary progressive multiple sclerosis (PPMS), Gauging Gradations In MRI and Clinical Outcomes (ARPEGGIO), a Phase II study to evaluate laquinimod. This is an investigational, oral, immune modulator, for PPMS, which currently has no approved treatments. PPMS affects approximately 15 percent of all MS patients […]
